Drug Delivery Technology Market by Route of Administration (Oral (Solid)  Pulmonary (Nebulizer)  Injectable (Device)  Ocular (Liquid)  Topical (Solid)  Implantable (Active)  Transmucosal (Oral))  Patient Care Setting (Hospital  ASC) - Global Forecast to 2

Drug Delivery Technology Market by Route of Administration (Oral (Solid) Pulmonary (Nebulizer) Injectable (Device) Ocular (Liquid) Topical (Solid) Implantable (Active) Transmucosal (Oral)) Patient Care Setting (Hospital ASC) - Global Forecast to 2

MarketsandMarkets | ID: 1541224005674 | Published at: 2017-01-12 | Pages: 254

  • €4.821,70


The drug delivery technology market is projected to reach USD 1,669.40 billion by 2021 from USD 1,179.20 billion in 2016, at a CAGR of 7.2% during the forecast period.
Increasing prevalence of chronic diseases, increasing demand for biologics, technological advancements, and new product launches are the factors driving the growth of this market. Whereas, self-administration & home care and rising demand for biosimilars and generic drugs offer significant growth opportunities for players operating in this market. On the other hand, risk of needle-stick injuries and side effects of drugs may restraint the growth of the market.
The drug delivery technology market is segmented based on route of administration, facility of use, and region. On the basis of route of administration, the market is segmented into oral, injectable, topical, nasal, ocular, pulmonary, implantable, and transmucosal. In 2016, the oral drug delivery segment is expected to account for the largest share of the market. This can be attributed to the wide range of benefits associated with oral drugs. The oral route of administration is one of the simplest, most convenient, and safest routes.
On the basis of facility of use, the market is segmented into the hospitals, ambulatory surgical centers/clinics, home care settings, diagnostic centers, and other facilities of use. In 2016, the hospitals segment is expected to account for the largest share of the market. This can be primarily attributed to advantages such as the significant number of inpatient and outpatient visits in hospitals as compared to other end users and the requirement of large volumes of drugs and their respective delivery devices to cater to the demand of this patient pool.
Asia is expected to be fastest-growing region in the drug delivery technology market from 2016 to 2021. Opportunities in the Asian market have attracted huge investments by major companies in the area of R&D activities. In addition, the region has low costs of labor and clinical trials, which has further served to draw market players to Asia.
Prominent players in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).
Research Coverage:
The report defines, describes, and forecast the drug delivery technology market on the basis of route of administration, facility of use, and region. It provides detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as joint ventures, mergers and acquisitions, new product developments, and expansions in the drug delivery technology market across to four main regions, namely, North America, Asia, Europe, and RoW.

Reasons to buy the report:
The report on the drug delivery technology market provides quantitative information for clients seeking market size information on various segments of this market. This report also provides access to the quantitative data on the drug delivery technology market. This report covers –
• Current and forecast assessment of the drug delivery technology market.
• Country-wise assessment of each of the segments
• Global market share analysis for major segments of the drug delivery technology market
• Adoption trends of various drug delivery technologies for major geographic markets
• Five-year coverage of strategic developments of top players in the drug delivery technology market
• Product Portfolio mapping of leading players in the drug delivery technology market

TABLE OF CONTENTS

1 INTRODUCTION 20

  • 1.1 OBJECTIVES OF THE STUDY 20
  • 1.2 MARKET DEFINITION 20
  • 1.3 MARKET SCOPE 21
    • 1.3.1 MARKETS COVERED 21
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 24
  • 1.4 CURRENCY 24
  • 1.5 LIMITATIONS 24
  • 1.6 MARKET STAKEHOLDERS 24
    2 RESEARCH METHODOLOGY 25
  • 2.1 MARKET SIZE ESTIMATION 26
  • 2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 29
  • 2.3 KEY DATA FROM SECONDARY SOURCES 30
  • 2.4 KEY DATA FROM PRIMARY SOURCES 31
  • 2.5 ASSUMPTIONS FOR THE STUDY 31
    3 EXECUTIVE SUMMARY 32
    4 PREMIUM INSIGHTS 36
  • 4.1 TOPICAL DRUG DELIVERY: MARKET OVERVIEW 36
  • 4.2 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE 37
  • 4.3 SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM 38
  • 4.4 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION 39
  • 4.5 GEOGRAPHICAL SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET 39
    5 MARKET OVERVIEW 40
  • 5.1 INTRODUCTION 41
  • 5.2 MARKET DYNAMICS 41
  • 5.3 DRIVERS 42
    • 5.3.1 RISING PREVALENCE OF CHRONIC DISEASES 42
    • 5.3.2 GROWTH IN THE BIOLOGICS MARKET 43
    • 5.3.3 TECHNOLOGICAL ADVANCEMENT AND NEW PRODUCT LAUNCHES 44
  • 5.4 RESTRAINTS 45
    • 5.4.1 RISK OF NEEDLESTICK INJURIES AND SIDE EFFECTS OF DRUGS 45
    • 5.4.2 PRODUCT RECALLS 46
  • 5.5 OPPORTUNITIES 47
    • 5.5.1 SELF-ADMINISTRATION AND HOME CARE 47
    • 5.5.2 RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS 48
      • 5.5.2.1 Biosimilars 48
      • 5.5.2.2 Generic drugs 48
    • 5.5.3 FOCUS ON OVERCOMING UNMET MEDICAL NEEDS 49
    • 5.5.4 EMERGING MARKETS 49
  • 5.6 CHALLENGES 50
    • 5.6.1 PATENT EXPIRY AND PATENT CLIFF 50
    • 5.6.2 PRICING PRESSURE 51
      6 REGULATORY SCENARIO 52
  • 6.1 INTRODUCTION 52
  • 6.2 DRUG APPROVAL IN THE U.S. 52
  • 6.3 DRUG APPROVAL IN EUROPE 54
    7 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION 55
  • 7.1 INTRODUCTION 56
  • 7.2 ORAL DRUG DELIVERY 57
    • 7.2.1 SOLID ORAL DRUGS 58
      • 7.2.1.1 Tablets 60
      • 7.2.1.2 Capsules 60
      • 7.2.1.3 Powders 61
      • 7.2.1.4 Pills 62
    • 7.2.2 LIQUID ORAL DRUGS 63
      • 7.2.2.1 Solutions 64
      • 7.2.2.2 Syrups 64
    • 7.2.3 SEMI-SOLID ORAL DRUGS 65
      • 7.2.3.1 Gels 66
      • 7.2.3.2 Emulsions 67
      • 7.2.3.3 Elixirs 67
  • 7.3 PULMONARY DRUG DELIVERY 68
    • 7.3.1 FORMULATIONS 69
    • 7.3.2 DEVICES 70
      • 7.3.2.1 Metered Dose Inhalers 71
      • 7.3.2.2 Dry Powder Inhalers 72
      • 7.3.2.3 Nebulizers 73
        • 7.3.2.3.1 Jet nebulizers 74
        • 7.3.2.3.2 Ultrasonic nebulizers 75
        • 7.3.2.3.3 Soft mist nebulizers 76
  • 7.4 INJECTABLE DRUG DELIVERY 77
    • 7.4.1 DEVICES 77
      • 7.4.1.1 Conventional Injection Devices 78
        • 7.4.1.1.1 By material 79
        • 7.4.1.1.2 Glass 80
        • 7.4.1.1.3 Plastic 81
        • 7.4.1.1.4 By product 82
          • 7.4.1.1.4.1 Fillable syringes 82
          • 7.4.1.1.4.2 Prefilled syringes 83
        • 7.4.1.1.5 By usability 84
          • 7.4.1.1.5.1 Reusable syringes 84
          • 7.4.1.1.5.2 Disposable syringes 85
      • 7.4.1.2 Self-injection devices 86
        • 7.4.1.2.1 Needle-free injectors 87
        • 7.4.1.2.2 Autoinjectors 88
        • 7.4.1.2.3 Pen injectors 89
        • 7.4.1.2.4 Wearable injectors 90
      • 7.4.1.3 Other Injector Devices 90
    • 7.4.2 FORMULATIONS 91
      • 7.4.2.1 Conventional drug delivery 92
      • 7.4.2.2 Novel drug delivery formulations 93
      • 7.4.2.3 Long-acting injection formulations 95
  • 7.5 OCULAR DRUG DELIVERY 96
    • 7.5.1 FORMULATIONS 97
      • 7.5.1.1 Liquid Formulations 98
        • 7.5.1.1.1 Eye Drops 99
        • 7.5.1.1.2 Liquid Sprays 100
      • 7.5.1.2 Semi-solid Formulations 101
        • 7.5.1.2.1 Gels 102
        • 7.5.1.2.2 Eye Ointments 102
    • 7.5.2 OCULAR DEVICES 103
      • 7.5.2.1 Drug-coated Contact Lenses 104
      • 7.5.2.2 Ocular Inserts 105
  • 7.6 NASAL DRUG DELIVERY 106
    • 7.6.1 NASAL DROPS 107
    • 7.6.2 NASAL SPRAYS 108
    • 7.6.3 NASAL POWDERS 108
    • 7.6.4 NASAL GELS 109
  • 7.7 TOPICAL DRUG DELIVERY 110
    • 7.7.1 FORMULATIONS 111
      • 7.7.1.1 Liquid Topical Drug Delivery 112
        • 7.7.1.1.1 Solutions 113
        • 7.7.1.1.2 Suspensions 114
      • 7.7.1.2 Semi-solid topical drug delivery 114
        • 7.7.1.2.1 Creams 116
        • 7.7.1.2.2 Gels 116
        • 7.7.1.2.3 Ointments 117
        • 7.7.1.2.4 Pastes 118
        • 7.7.1.2.5 Lotions 118
      • 7.7.1.3 Solid topical drug delivery 119
        • 7.7.1.3.1 Suppositories 120
        • 7.7.1.3.2 Powders 121
    • 7.7.2 DEVICES (TRANSDERMAL DRUG DELIVERY) 121
      • 7.7.2.1 Transdermal patches 122
      • 7.7.2.2 Transdermal Gels 123
  • 7.8 IMPLANTABLE DRUG DELIVERY 124
    • 7.8.1 ACTIVE IMPLANTABLE DRUG DELIVERY 125
    • 7.8.2 PASSIVE IMPLANTABLE DRUG DELIVERY 126
  • 7.9 TRANSMUCOSAL DRUG DELIVERY 126
    • 7.9.1 ORAL TRANSMUCOSAL DRUG DELIVERY 128
      • 7.9.1.1 Buccal Drug Delivery 129
      • 7.9.1.2 Sublingual drug delivery 130
    • 7.9.2 OTHER TRANSMUCOSAL DRUG DELIVERY 131
      • 7.9.2.1 Rectal Transmucosal Drug Delivery 132
      • 7.9.2.2 Vaginal Transmucosal Drug Delivery 132
        8 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE 134
  • 8.1 INTRODUCTION 135
  • 8.2 HOSPITALS 137
  • 8.3 AMBULATORY SURGICAL CENTERS/CLINICS 138
  • 8.4 HOME CARE SETTINGS 138
  • 8.5 DIAGNOSTIC CENTERS 139
  • 8.6 OTHER FACILITIES OF USE 140
    9 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION 141
  • 9.1 INTRODUCTION 142
  • 9.2 NORTH AMERICA 143
    • 9.2.1 U.S. 146
    • 9.2.2 CANADA 148

  • 9.3 EUROPE 149
    • 9.3.1 GERMANY 152
    • 9.3.2 FRANCE 154
    • 9.3.3 U.K. 155
    • 9.3.4 REST OF EUROPE (ROE) 157
  • 9.4 ASIA 158
    • 9.4.1 JAPAN 161
    • 9.4.2 CHINA 163
    • 9.4.3 INDIA 164
    • 9.4.4 REST OF ASIA 166
  • 9.5 REST OF THE WORLD 167
    10 COMPETITIVE LANDSCAPE 170
  • 10.1 OVERVIEW 170
  • 10.2 MARKET SHARE ANALYSIS 171
  • 10.3 COMPETITIVE SITUATIONS & TRENDS 173
    • 10.3.1 PRODUCT LAUNCHES & APPROVALS 175
    • 10.3.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 176
    • 10.3.3 ACQUISITIONS, MERGERS, AND JOINT VENTURES 177
    • 10.3.4 EXPANSIONS 177
      11 COMPANY PROFILES 178
      (Overview, Products and Services, Financials, Strategy & Development)*
  • 11.1 INTRODUCTION 178
  • 11.2 JOHNSON & JOHNSON SERVICES, INC. 179
  • 11.3 NOVARTIS AG 187
  • 11.4 F. HOFFMANN-LA ROCHE LTD. 192
  • 11.5 PFIZER, INC. 195
  • 11.6 BAYER AG 202
  • 11.7 ANTARES PHARMA, INC. 205
  • 11.8 BECTON, DICKINSON AND COMPANY 207
  • 11.9 GLAXOSMITHKLINE PLC 211
  • 11.10 3M 216
  • 11.11 MERCK & CO., INC. 218
  • 11.12 SANOFI 223
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

12 APPENDIX 227

  • 12.1 INSIGHTS FROM INDUSTRY EXPERTS 227
  • 12.2 DISCUSSION GUIDE 228
  • 12.3 OTHER RECENT DEVELOPMENTS 232
  • 12.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 247
  • 12.5 AVAILABLE CUSTOMIZATIONS 249
  • 12.6 RT: REAL-TIME MARKET INTELLIGENCE 250
  • 12.7 RELATED REPORTS 251
  • 12.8 AUTHOR DETAILS 252

LIST OF TABLES

TABLE 1 INDICATIVE LIST OF BIOLOGICS APPROVED BY FDA (2015 & 2016) 43
TABLE 2 MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY TECHNOLOGY MARKET, 2015 46
TABLE 3 PATENT EXPIRY OF DRUGS, 2014–2015 50
TABLE 4 LIST OF REGULATORY AUTHORITIES, BY COUNTRY 52
TABLE 5 SOME OF THE RECENTLY APPROVED DRUGS BY FDA 53
TABLE 6 SOME OF THE RECENTLY APPROVED DRUGS IN EUROPE 54
TABLE 7 DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 57
TABLE 8 ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 58
TABLE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 58
TABLE 10 ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS,
BY DOSAGE FORM, 2014–2021 (USD BILLION) 59
TABLE 11 ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS,
BY REGION, 2014–2021 (USD BILLION) 59
TABLE 12 SOLID ORAL DRUGS MARKET SIZE FOR TABLETS, BY REGION,
2014–2021 (USD BILLION) 60
TABLE 13 SOLID ORAL DRUGS MARKET SIZE FOR CAPSULES, BY REGION,
2014–2021 (USD BILLION) 61
TABLE 14 SOLID ORAL DRUGS MARKET SIZE FOR POWDERS, BY REGION,
2014–2021 (USD BILLION) 62
TABLE 15 SOLID ORAL DRUGS MARKET SIZE FOR PILLS, BY REGION,
2014–2021 (USD BILLION) 62
TABLE 16 LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2014–2021 (USD BILLION) 63
TABLE 17 LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 63
TABLE 18 LIQUID ORAL DRUGS MARKET SIZE FOR SOLUTIONS, BY REGION,
2014–2021 (USD BILLION) 64
TABLE 19 LIQUID ORAL DRUGS MARKET SIZE FOR SYRUPS, BY REGION,
2014–2021 (USD BILLION) 65
TABLE 20 SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY DOSAGE FORM, 2014–2021 (USD BILLION) 65
TABLE 21 SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 66
TABLE 22 SEMI-SOLID ORAL DRUGS MARKET SIZE FOR GELS, BY REGION,
2014–2021 (USD BILLION) 66
TABLE 23 SEMI-SOLID ORAL DRUGS MARKET SIZE FOR EMULSIONS, BY REGION,
2013–2020 (USD BILLION) 67
TABLE 24 SEMI-SOLID ORAL DRUGS MARKET SIZE FOR ELIXIRS, BY REGION,
2014–2021 (USD MILLION) 68
TABLE 25 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 69
TABLE 26 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 69
TABLE 27 PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 70
TABLE 28 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 71
TABLE 29 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 71
TABLE 30 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE FOR METERED DOSE INHALERS, BY REGION, 2014–2021 (USD BILLION) 72
TABLE 31 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE FOR DRY POWDER INHALERS, BY REGION, 2013–2020 (USD MILLION) 73
TABLE 32 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE FOR NEBULIZERS, BY TYPE, 2013–2020 (USD MILLION) 74
TABLE 33 PULMONARY DRUG DELIVERY DEVICES MARKET SIZE FOR NEBULIZERS,
BY REGION, 2014–2021 (USD MILLION) 74
TABLE 34 JET NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 75
TABLE 35 ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 76
TABLE 36 SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 76
TABLE 37 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 77
TABLE 38 INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 78
TABLE 39 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 79
TABLE 40 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL,
2014–2021 (USD BILLION) 79
TABLE 41 CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 80
TABLE 42 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 81
TABLE 43 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 82
TABLE 44 CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 83
TABLE 45 CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 84
TABLE 46 CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY,
2014–2021 (USD BILLION) 84
TABLE 47 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 85
TABLE 48 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 86
TABLE 49 SELF-INJECTION DEVICES MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 87
TABLE 50 SELF-INJECTION DEVICES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 87
TABLE 51 NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 88
TABLE 52 AUTOINJECTORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 88
TABLE 53 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 89
TABLE 54 PEN INJECTORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 89
TABLE 55 WEARABLE INJECTORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 90
TABLE 56 OTHER INJECTOR DEVICES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 91
TABLE 57 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 92
TABLE 58 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 92
TABLE 59 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 93
TABLE 60 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 93
TABLE 61 NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 94
TABLE 62 NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 94
TABLE 63 LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 95
TABLE 64 OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 96
TABLE 65 OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 97
TABLE 66 OCULAR DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 97
TABLE 67 OCULAR DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 98
TABLE 68 LIQUID OCULAR FORMULATIONS MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 98
TABLE 69 LIQUID OCULAR FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 99
TABLE 70 COMMERCIALLY AVAILABLE EYE DROPS 99
TABLE 71 EYE DROPS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 100
TABLE 72 LIQUID SPRAYS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 100
TABLE 73 SEMI-SOLID OCULAR FORMULATIONS MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 101
TABLE 74 SEMI-SOLID OCULAR FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 101
TABLE 75 OCULAR GELS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 102
TABLE 76 EYE OINTMENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 103
TABLE 77 OCULAR DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 103
TABLE 78 OCULAR DRUG DELIVERY DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 104
TABLE 79 DRUG-COATED CONTACT LENSES MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 104
TABLE 80 OCULAR INSERTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 105
TABLE 81 NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 106
TABLE 82 NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 107
TABLE 83 NASAL DROPS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 107
TABLE 84 NASAL SPRAYS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 108
TABLE 85 NASAL POWDERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 109
TABLE 86 NASAL GELS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 109
TABLE 87 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 110
TABLE 88 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 111
TABLE 89 TOPICAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 111
TABLE 90 TOPICAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 112
TABLE 91 LIQUID TOPICAL FORMULATIONS MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 112
TABLE 92 LIQUID TOPICAL FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 113
TABLE 93 TOPICAL SOLUTIONS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 113
TABLE 94 TOPICAL SUSPENSIONS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 114
TABLE 95 SEMI-SOLID TOPICAL FORMULATIONS MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 115
TABLE 96 SEMI-SOLID TOPICAL FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 115
TABLE 97 TOPICAL CREAMS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 116
TABLE 98 TOPICAL GELS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 117
TABLE 99 TOPICAL OINTMENTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 117
TABLE 100 TOPICAL PASTES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 118
TABLE 101 TOPICAL LOTIONS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 119
TABLE 102 SOLID TOPICAL FORMULATIONS MARKET SIZE, BY DOSAGE FORM,
2014–2021 (USD BILLION) 119
TABLE 103 SOLID TOPICAL FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 120
TABLE 104 TOPICAL SUPPOSITORIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 120
TABLE 105 TOPICAL POWDERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 121
TABLE 106 TRANSDERMAL DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 122
TABLE 107 TRANSDERMAL DRUG DELIVERY DEVICES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 122
TABLE 108 TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 123
TABLE 109 TRANSDERMAL GELS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 123
TABLE 110 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 124
TABLE 111 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 125
TABLE 112 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 125
TABLE 113 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 126
TABLE 114 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 127
TABLE 115 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 127
TABLE 116 ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 128
TABLE 117 ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 128
TABLE 118 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 129
TABLE 119 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 130
TABLE 120 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 131
TABLE 121 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 131
TABLE 122 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY REGION, 2014–2021 (USD MILLION) 132
TABLE 123 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY REGION, 2014–2021 (USD MILLION) 133
TABLE 124 GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 136
TABLE 125 GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 136
TABLE 126 DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOSPITALS, BY REGION,
2014–2021 (USD BILLION) 137
TABLE 127 DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR AMBULATORY SURGICAL CENTERS/CLINICS, BY REGION, 2014–2021 (USD BILLION) 138
TABLE 128 DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOME CARE SETTINGS,
BY REGION, 2014–2021 (USD BILLION) 139
TABLE 129 DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR DIAGNOSTIC CENTERS,
BY REGION, 2014–2021 (USD BILLION) 140
TABLE 130 DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR OTHER FACILITIES OF USE,
BY REGION, 2014–2021 (USD BILLION) 140
TABLE 131 DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION,
2014-2021 (USD BILLION) 142
TABLE 132 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION) 145
TABLE 133 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 145
TABLE 134 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY FACILITY OF USE, 2014–2021 (USD BILLION) 146
TABLE 135 U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 147
TABLE 136 U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 147
TABLE 137 CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 148
TABLE 138 CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE, 2014–2021 (USD BILLION) 149
TABLE 139 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 151
TABLE 140 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 151
TABLE 141 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE, 2014–2021 (USD BILLION) 152
TABLE 142 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 153
TABLE 143 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE, 2014–2021 (USD BILLION) 153
TABLE 144 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 154
TABLE 145 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE, 2014–2021 (USD BILLION) 155
TABLE 146 U.K.: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 156
TABLE 147 U.K.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 156
TABLE 148 ROE: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 157
TABLE 149 ROE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 158
TABLE 150 ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY,
2014-2021 (USD BILLION) 160
TABLE 151 ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 160
TABLE 152 ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 161
TABLE 153 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 162
TABLE 154 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 162
TABLE 155 CHINA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 163
TABLE 156 CHINA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 164
TABLE 157 INDIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 165
TABLE 158 INDIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 165
TABLE 159 ROA: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 166
TABLE 160 ROA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER,
2014–2021 (USD BILLION) 167
TABLE 161 ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE,
BY ROUTE OF ADMINISTRATION, 2014–2021 (USD BILLION) 169
TABLE 162 ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2014–2021 (USD BILLION) 169
TABLE 163 PRODUCT LAUNCHES & APPROVALS, 2014–2016 175
TABLE 164 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS, 2014–2016 176
TABLE 165 ACQUISITIONS, MERGERS, AND JOINT VENTURES, 2014–2016 177
TABLE 166 EXPANSIONS, 2014–2016 177
TABLE 167 EXCHANGE RATES (UTILIZED FOR CONVERSION OF CHF TO USD) 192
TABLE 168 EXCHANGE RATE (UTILIZED FOR CONVERSION OF EUR TO USD) 202
TABLE 169 EXCHANGE RATE (UTILIZED FOR CONVERSION OF GBP TO USD) 211
TABLE 170 EXCHANGE RATE (UTILIZED FOR CONVERSION OF EUR TO USD) 223


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 25
FIGURE 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 27
FIGURE 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 28
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 28
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
FIGURE 1 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION (2016) 32
FIGURE 2 ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS,
BY DOSAGE FORM, 2016 VS. 2021 (USD BILLION) 33
FIGURE 3 DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY FACILITY OF USE,
2016 VS. 2021 (USD BILLION) 34
FIGURE 4 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 35
FIGURE 5 EASE OF USE, RISING PREVALENCE OF CHRONIC DISEASES ARE DRIVING MARKET GROWTH 36
FIGURE 6 HOSPITALS SEGMENT TO HOLD LARGEST MARKET SHARE FROM 2016 TO 2021 37
FIGURE 7 TABLETS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2016 38
FIGURE 8 ORAL DRUG DELIVERY TO HOLD LARGEST SHARE IN THE MARKET IN 2016 39
FIGURE 9 CHINA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 39
FIGURE 10 DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 11 TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 56
FIGURE 12 THE HOSPITALS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE DRUG DELIVERY TECHNOLOGY MARKET IN 2016 135
FIGURE 13 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 144
FIGURE 14 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 150
FIGURE 15 ASIA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 159
FIGURE 16 ROW: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 168
FIGURE 17 PRODUCT LAUNCHES & APPROVALS: KEY GROWTH STRATEGY ADOPTED
BY PLAYERS IN THE DRUG DELIVERY TECHNOLOGY MARKET (2014–2016) 170
FIGURE 18 GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER (2015) 171
FIGURE 19 MARKET EVOLUTION FRAMEWORK: PRODUCT LAUNCHES & APPROVALS ARE FUELING MARKET GROWTH 173
FIGURE 20 BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES & APPROVALS IS THE KEY GROWTH STRATEGY ADOPTED BY LEADING MARKET PLAYERS 174
FIGURE 21 GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS 178
FIGURE 22 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2015) 179
FIGURE 23 NOVARTIS AG: COMPANY SNAPSHOT (2015) 187
FIGURE 24 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2015) 192
FIGURE 25 PFIZER, INC.: COMPANY SNAPSHOT (2015) 195
FIGURE 26 BAYER AG: COMPANY SNAPSHOT (2015) 202
FIGURE 27 ANTARES PHARMA, INC.: COMPANY SNAPSHOT (2015) 205
FIGURE 28 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2015) 207
FIGURE 29 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2015) 211
FIGURE 30 3M: COMPANY SNAPSHOT (2015) 216
FIGURE 31 MERCK & CO., INC.: COMPANY SNAPSHOT (2015) 218
FIGURE 32 SANOFI: COMPANY SNAPSHOT (2015) 223

Get in touch!

Looking for sample pages? Or want to speak to someone about discounts?

Please leave your details and we'll get back to you as soon as we can!